Organetix Inc. Announces Success in the Results of Its Recent Hepatitis C Quality of Life Study: The Board of Directors Appoints Dr. Jose Cabanillas to Serve as Executive Vice President of Research & Development

Business Wire - August 3, 2004

NEW YORK -- Organetix Inc. announced today that it has received the results of its study to determine the effectiveness of its A4+L Liver Product on the quality of life of Hepatitis C patients. The study was designed by independent doctors in the USA and Peru and was conducted in Peru. Based on the results reported by the doctors, who tested and examined the patients, the Company has decided that there was significant success in the areas of depression, health-related quality of life burden, clinical symptoms and nutritional status to continue further research and development of the A4+L Liver Product.

As quoted by Dr. Joseph Nystrom, Chief of Staff Elect at the East Pasco Medical Center, located in the Tampa Bay Metropoliton area: "In summary, the Nutraceutical Product A4+L has enormous potential as therapy for emotional and physical suffering of the burgeoning number of Hepatitis C sufferers. A larger placebo controlled long term study is warranted. Further study of A4+L may reveal it to be useful in other disease processes as well."

Accordingly, Organetix, Inc. will now formalize discussions with certain investment bankers. With the recent success in the results of the Quality of Life Study, Organetix, Inc. is planning to complete a significant fund raising as soon as possible.

In addition, the Company announced that its Board of Directors has appointed Dr. Jose Cabanillas to serve as Executive Vice President of Research and Development. Dr. Cabanillas has been a speaker at conferences and seminars and has several credited publications in relevant journals. Using Integrative Medicine, his practice incorporates both modern biomedicine and natural healing methods. Dr. Cabanillas, through a variety of roles, has in the past been active with the University of British Columbia in Vancouver, Canada. He recently lectured to Cornell University's pre-med students at their bio-diversity laboratory in Punta Cana, Dominican Republic.

About Organetix, Inc.

Organetix, Inc. is a biotechnology company that is in the process of treating patients with a unique nutraceutical that appears to relieve symptoms of Hepatitis C. Organetix has the exclusive worldwide rights for this nutraceutical product. Hepatitis C is a life-threatening, blood-borne, liver disease that is caused by a virus. It is estimated that millions of individuals worldwide are infected with Hepatitis C making it one of the greatest public health threats faced in recent years.

Statements contained in this press release, which are not historical facts, are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based largely on the Company's expectations and are subject to a number of risks and uncertainties beyond the Company's control, including but not limited to economic, competitive and other factors affecting the Company's operations, management team effectiveness, expansion strategies, available financing, market prices and recovery costs, government regulations involving the Company, facts and events not known at the time of this release, and other factors discussed in the Company's filings with the Securities and Exchange Commission.

These statements are not guarantees of future performance and readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update publicly any forward-looking statements.

CONTACT: Corporate Communications Group, Inc.

David Pomerantz, 516-791-0000 ext. 102, david@ccgnewyork.com

SOURCE: Organetix, Inc.

040803
BW040803

Copyright © 2004 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .